Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialTools Backen, Alison C. and Lopes, Andre and Wasan, Harpreet and Palmer, Daniel H. and Duggan, Marian and Cunningham, David and Anthoney, Alan and Corrie, Pippa G. and Madhusudan, Srinivasan and Maraveyas, Anthony and Ross, Paul J. and Waters, Justin S. and Steward, William P. and Rees, Charlotte and McNamara, Mairéad G. and Beare, Sandy and Bridgewater, John A. and Dive, Caroline and Valle, Juan W. (2018) Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer . ISSN 0007-0920 Full text not available from this repository.
Official URL: https://www.nature.com/articles/s41416-018-0132-8
AbstractBACKGROUND: Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes.
Actions (Archive Staff Only)
|